Protocol Title: Clinical Investigation of Visual Acuity in  Contact [CONTACT_624165]-6503  
 
Version: 2.0   
 
Date: 24 April 2023  
  
Investigational Products: Product  (Investigational Lubricating Eye Drop  in a Novelia
® 
Multidose Eyedropper) 
 Approved Products: Blink
® Tears lubricating eyedrops in a multidose bottle   
 Keywords: artificial tears, non-dispensing, visual acuity, dry eye   Statement of Compliance to protocol, GCP and applicable regulatory guidelines:  
This clinical trial will be conducted in compliance with ISO [ZIP_CODE]:2020 Clinical investigation of medical devices 
for human subjects – Good clinical practice,
1 International Council for Harmonization Good Clinical Practice 
ICH E6(R2) (ICH GCP)4 guidelines, and the Declaration of Helsinki.2 
 
Confidentiality Statement: 
This document contains confidential information, which should not be copi[INVESTIGATOR_530], referred to, released or published 
without written approval from [COMPANY_012] Vision Care, Inc. The information may not be disclosed to 
others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee 
approval and informed consent, or as required by [CONTACT_624166], Federal and State Laws, as applicable. Persons to 
whom this information is disclosed must be informed that this information is privileged and confidential and that 
it should not be further disclosed without the written permission of [COMPANY_012] Vision Care, Inc. Any 
supplemental information that may be added to this document is also confidential and proprietary to Johnson & 
Johnson Vision Care, Inc. and must be kept in confidence in the same manner as the contents of this document.   Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831062] Artic les ..................................................................................................... ................. 20  
6.2. Ancillary Supplies/Products ................................................................................................... ............. [ADDRESS_831063] Ar ticles ............................................................................................... ............ 22  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 2 of 108JJVC CONFIDENTIAL
7. STUDY EVALUAT IONS ............................................................................................................. ......... 22  
7.1. Time and Event Schedule ....................................................................................................... ............ 22  
7.2. Detailed Study Procedures ..................................................................................................... ............. 23  
VISIT 1 ....................................................................................................................... ................................ 23  
FINAL EVALUATION .............................................................................................................. ................ 27  
7.3. Unscheduled Visits ............................................................................................................ ................. 27  
7.4. Laboratory Procedures ........................................................................................................................ 28  
8. SUBJECTS COMPLETION/WITHDRAWAL ...................................................................................... 28  
8.1. Completion Criteria ........................................................................................................... ................. 28  
8.2. Withdrawal/Discontinuation from the Study ..................................................................................... . 29 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION .......................................... 29 
9.1. Systemic Medications .......................................................................................................... ............... 29  
10. DEVIATIONS FROM THE PROTOCOL .............................................................................................. 30  
11. STUDY TERMINATION ....................................................................................................................... 31  
12. PROCEDURE FOR HANDLING PRODUC T QUALITY COMPLAINTS .......................................... 32  
13. ADVERSE EVENTS ................................................................................................................ .............. 32  
13.1.  Definitions and Cl assifica tions ............................................................................................... ............ 32  
13.2.  Assessing Adverse Events ...................................................................................................... ............ 34  
13.2.1.  Causality Assessment........................................................................................................... .. 34 
13.2.2.  Severity Assessment ........................................................................................................... ... 34  
13.3.  Documentation and Follow-Up of Adverse Events ............................................................................ 35  
13.4.  R eporting Adverse Events ...................................................................................................... ............ 36  
13.4.1.  Reporting Adverse Even ts to S ponsor ................................................................................... 36  
13.4.2.  Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities ................... [ADDRESS_831064] KE EPI[INVESTIGATOR_1645]/ARCHIVING ............................................................ 39  
15.1.  Electronic Case Report Form/Data Collection ................................................................................... . 39 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831065] ................................................................................................................ .................... 40  
15.3.  Trial Registration on ClinicalTrials.gov....................................................................................... ....... 40  
16. DATA MANAGE MENT ............................................................................................................... ......... 40  
16.1.  Access to Source Data/Document ................................................................................................ ....... 40  
16.2.  Confidentiality of  Information ................................................................................................ ............ 40  
16.3.  Data Quality Assurance ........................................................................................................ .............. 40  
16.4.  Data Monitoring Committee (DMC) ............................................................................................... ... [ADDRESS_831066] (IEC/IRB) ......................................... [ADDRESS_831067] RETENTION ........................................................................................................ ... 44  
20. FINANCIAL CONSID ERATIONS ...................................................................................................... .. 44 
21. PUBLICATION ................................................................................................................... ................... 44  
22. REFERENCES .................................................................................................................... .................... 44  
APPENDIX A: PATIENT REPORTED OUT COMES (STUDY QUE STIONNAIRES) ................................... 46  
APPENDIX B: PATIENT INSTRUCTION GUIDE ......................................................................................... .. 47 
APPENDIX 
C: PACKAGE INSERT  (APPROVED PR ODUCT) ....................................................................... 48  
APPENDIX D: ..................................................................... [ADDRESS_831068] REPORTED OCULAR  SYMPTOMS/PROBLEMS ....................................................... [ADDRESS_831069] ANCE LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE .............................. 83  
 DISTANCE AND NEAR SNELLEN VI SUAL ACUITY EVALUATION ..................................... 87  
APPENDIX E:  GUIDELINES FOR COVID-19 RISK MITIGATION............................................. 96  
PROTOCOL COMPLIANCE INVESTI GATOR(S) SIGNATURE [CONTACT_1783] ...................................................... [ADDRESS_831070] OF TABLES 
Table 1: Target number of subjects by [CONTACT_3725] .................................................................................... ....................... [ADDRESS_831071] assignment to treatments (eye drops) ......................................................................... ............... 20  
Table 3: Test Articles ........................................................................................................ ................................... 20  
Table 4: Ancilla ry Supplies ................................................................................................... ............................... 21  
Table 5: Time and Events ...................................................................................................... ............................... 22  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 4 of 108JJVC CONFIDENTIAL
Table 6: Systemic medications list ............................................................................................ ........................... 29  
Table 7: Disallowed syst emic antihistamines ................................................................................... .................... 30  
Table 8: Examples of major a nd minor protocol  deviations ...................................................................... ........... 31  
Table 9: Descriptive Summary of Monocular LogMAR Visual Acuity from  – Per Protocol Population
 .............................................................................................................................. ................................................ 37  
Table 10: Power for the Primary Endpoint ...................................................................................... ..................... [ADDRESS_831072] OF FIGURES 
Figure 1: Study Flowchart .................................................................................................................................... 13  
Figure 2: The mechanism for dispensing drops in the Novelia® system .............................................................. 15  
 
 
    
 
    
 
      Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831073] achieve visual acuity of 20/[ADDRESS_831074] lenses. 
 
Eligibility Criteria - Exclusion Potential subjects who meet any of the following criteria will be excluded 
from participating in the study:  
 
Exclusion Criteria following Screening The subject must not: 
1. Be currently pregnant or lactating. 
2. Be diabetic.  
3. Be currently using any ocular medications or have any ocular 
infection of any type which may interfere with the clinical trial 
(at the investigator’s discretion). 
4. By [CONTACT_6270]-report, have any ocular or systemic disease, allergies, 
infection, or use of medication that might contraindicate or 
interfere with the clinical trial, or otherwise compromise study 
endpoints, including infectious diseas e (e.g., hepatitis, 
tuberculosis), contagious immunosuppressive disease (e.g., 
Human Immunodeficiency Virus [HIV]), autoimmune disease 
(e.g., rheumatoid arthritis, Sjögren’s syndrome), or history of 
serious mental illness or seizures. See section 9.[ADDRESS_831075] habitually worn rigid gas permeable (RGP) lenses, 
orthokeratology lenses, or hybrid lenses (e.g., SynergEyes, SoftPerm) within the past [ADDRESS_831076] participated in any phar maceutical or medical device 
related clinical trial within 14 days prior to study enrollment.  
7. Be an employee (e.g., Investigator, Coordinator, Technician) or 
immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site. 
8. Be a current habitual user of pr escription medication to treat dry 
eye and ocular discomfort, ocular steroids, or any medication (RX or OTC) except artificial tears, that would interfere with the 
clinical study (at the discretion of the investigator).  
9. Have any known allergy or sensitivity to ingredients that the investigational product may contain (e.g., Sodium Chlorite, Boric 
Acid, Sodium Borate Decahydrate, Sodium Chloride, Potassium 
Chloride, Calcium Chloride Dihydrate, Magnesium Chloride 
Hexahydrate, Polyethylene Glycol 400, Sodium Hyaluronate and 
Purified Water). 
 Exclusion Criteria at Baseline Evaluation 
The subject must not: 
10. Have clinically significant (grade 3 or higher on the FDA grading 
scale) slit lamp findings (e.g., corneal edema, neovascularization 
or staining, tarsal abnormalities, or bulbar injection) or other 
corneal or ocular disease or abnormalities that contraindicate participation or may otherwise compromise study endpoints 
(including entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 11 of 108JJVC CONFIDENTIAL
glaucoma, history of recurrent corneal erosions, aphakia, 
moderate or above corneal distortion, herpetic keratitis). 
11. Have a history of strabismus or amblyopia. 
12. Have had or have planned (within  the study period) any ocular or 
intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, cataract removal, retinal laser photocoagulation, etc.). 
13. Have any significant corneal distortion due to previous contact 
[CONTACT_13279], surgery, or pathology (At the discretion of the investigator).  
Disallowed 
Medications/Interventions Current habitual use of Prescription Medicines to treat dry eye or ocular discomfort, ocular steroids, or any medication (RX or OTC) that would 
interfere with the clinical study (at the discretion of the investigator). 
Measurements and Procedures LogMAR visual acuity, slit lamp finding using FDA scale, Snellen visual 
acuity, subject reported ocular symptoms 
Microbiology or Other Laboratory Testing None 
Study Termination The occurrence of a Serious Adverse Event (SAE) for which a causal 
relationship to a test article cannot be ruled out, will result in stoppi[INVESTIGATOR_624162]. In the event of a SAE, the 
Sponsor Medical Monitor may unmask the treatment regimen of subject(s) 
and may discuss this with the Principal Investigator [INVESTIGATOR_607921]. 
Ancillary Supplies/ Study-
Specific Materials ScleralFil (Bausch + Lomb), Fluorescein (Akorn, Inc.) or another country-specific alternative approved by [CONTACT_456].  
Principal Investigator(s) and Study Institution(s)/Site(s) A full list of Principal Investigators, clinical sites, and institutions is kept separately from the Study Protocol and is included in the study Trial 
Master File. 
 
  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 12 of 108JJVC CONFIDENTIAL
Figure 1: Study Flowchart  
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS 
Add   Near addition; the additional power required for near vision correction  
ADR   Adverse Drug Reaction 
AE   Adverse Event/Adverse Experience 
BCVA   Best Corrected Visual Acuity 
BSCVA   Best Spectacle Corrected Visual Acuity 
CFR   Code of Federal Regulations 
COM   Clinical Operations Manager 
COVID-[ADDRESS_831077] 
IB   Investigator’s Brochure 
ICF   Informed Consent Form 
ICH   International Council for Harmonization IDE   Investigational Device Exemption IEC   Independent Ethics Committee 
IRB   Institutional Review Board 
ISO   International Organization for Standardization 
ITT   Intention-to-Treat 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 13 of 108JJVC CONFIDENTIAL
JJVC   [COMPANY_012] Vision Care, Inc. 
LC   Limbus Center 
LogMAR  Logarithm of Minimal Angle of Resolution MedDRA
©  Medical Dictionary for Regulatory Activities 
MOP   Manual of Procedures 
NIH   National Institutes of Health 
OD   Right Eye 
OHRP   Office for Human Research Protections 
OHSR   Office for Human Subjects Research 
OS   Left Eye 
OU   Both Eyes 
PD   Protocol Deviation 
PHI   Protected Health Information 
PI   [INVESTIGATOR_624163]/Serious Adverse Experience 
SAP   Statistical Analysis Plan 
SAS   Statistical Analysis System 
SD   Standard Deviation 
VA   Visual Acuity 
  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 14 of 108JJVC CONFIDENTIAL
1. INTRODUCTION AND BACKGROUND 
It is estimated that Dry Eye Diseases (DED) affect approximately [ADDRESS_831078] 
been documented to induce conjunctival inflammation and tear-film instability in human and animal studies, highlighting the need for preservative-free options in topi[INVESTIGATOR_12469]
7. Given the potential of additional 
benefit of preservative-free topi[INVESTIGATOR_624164], JJV CEH has already introduced Blink® Tears Preservative 
Free lubricating eye drops in single dose vials. However, JJV CEH currently does not offer preservative-free 
topi[INVESTIGATOR_265217]  a multidose dropper.   
 This study will investigate a new investigational product  which contains the marketed formulation 
 in a Novelia
® eyedropper, along with the marketed Blink® Tears ([COMPANY_012] Surgical Vision, 
Santa Ana, CA) as a control in up to 3 clinical sites in the US. 
 
Figure 2: The mechanism for dispensing drops in the Novelia® system 
 
Figure 2 above shows the mechanism of drug delivery system utilized by a Novelia® (Nemera Inc, [LOCATION_009]) 
eyedropper where the squeezing action of the bottle/eyedropper opens a valve which facilitates the dispensing of a single drop. The intricate system of valves closes immediately which stops the potential backflow of the drop which comes into contact [CONTACT_265226]/external environment, hence maintaining sterility of the formulations 
contained in the bottle. 
1.1. Name [CONTACT_265244]: 
 
x Investigational Eye Drops  in a Novelia
® eyedropper, Product  (Test) 
x Approved Products: Blink® Tears eye Drops (Control) 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 15 of 108JJVC CONFIDENTIAL
Blink® Tears is a marketed product with preservatives while the investigational lubricating eye drops do not 
contain any preservatives and are mainta ined sterile in a multi-dose Novelia® eyedropper.  
1.2. Intended Use of Investigational Products 
The investigational eye drops are developed as preservative-free lubricating eye drops, and the other product, 
the control drop is CE approved and is a marketed eye drop, available over the counter (without a prescription) 
in the US.  
 The intended use of the study artificial tears is treatment of subjects with symptoms of ocular dryness. The 
indications for the investigational eyedrops are consistent with 21 CFR Part 349.60 pertaining to the demulcent 
eyedrops as per the FDA OTC monograph
8. The following are the indications: 
x For the temporary relief of burning and irritation due to dryness of the eye. 
x For the temporary relief of discomfort due to minor irritation of the eye or to exposure to wind or 
sun. 
x For use as a protectant against further irritation or to relieve dryness of eye. 
x For use as a lubricant to prevent further irritation or relieve dryness of the eye.  
In this study, the test articles will be  used over the soft spherical contact  [CONTACT_456100] a non-dispensing modality 
to assess visual acuity after instilla tion to support EU registration. In the EU, the eyedrops will be intended to 
be used with contact [CONTACT_13279].  
1.3. Summary of Findings from Nonclinical Studies 
All previous pre-clinical findings were deemed satisfact ory prior to proceeding with clinical trials on humans. 
For the most comprehensive nonclinical information re garding the investigational eye drops in a Novelia
® 
eyedropper, refer to the latest version of the Investigator’s Brochure9. 
1.4. Summary of Known Risks and Benefits to Human Subjects 
The following risks/adverse events can be associ ated with using artificial tears, in general: 
x There may be less comfort than when the drop was first placed on the eye. 
x The eyes may burn, sting and/or itch. 
x There may be a feeling of something in the eye (foreign body, scratched area). 
x There may be the potential for some temporary impairment due to peripheral infiltrates, peripheral 
corneal ulcers, and corneal erosion. 
x There may be the potential for other physiological observations, such as local or generalized edema, corneal neovascularization, corneal staining, injection, tarsal abnormalities, iritis, and conjunctivitis, some of which are clinically acceptable in low amounts. 
x There may be excessive watering, unusual eye secretions, or redness of the eye. 
x Poor visual acuity, blurred vision, rainbows or halos around objects, photosensitivity, or dry eyes may also occur if the drops are used continuously or for too long a time. 
 
There is no direct benefit to the subj ect for participating in the study, alt hough they will be able to try out new 
artificial tears. The information fr om this study will aid in the furt her development and design of new 
preservative free artificial tears.  
For the most comprehensive clinical information regarding the control eyedrops refer to the package insert 
(Appendix C). 
1.5. Relevant Literature References and Prior Clinical  Data Relevant to Prop osed Clinical Study 
Refer to the Investigator’s Brochure
9 and package insert for control eyedrops (Appendix C) for additional 
information.  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831079] registration in the European Union. 
2.2. Endpoints  
Primary Endpoint: 
x Monocular distance (4 m) High Luminance, Low Contrast (HLLC) logMAR visual acuity under high 
illumination 
 
Exploratory endpoints: 
The exploratory endpoints in this study are: 
x Slit lamp findings using FDA scale 
x Snellen best corrected distance visual acuity 
x Subject reported ocular symptoms 
x Number of adverse events 
x Number and reasons for discontinuation will be monitored 
x Contact [CONTACT_624167] 
2.3. Hypotheses 
Primary Hypothesis: 
x Monocular distance (4 m) High Luminance, Low Contrast (HLLC) logMAR visual acuity at 10-minute 
after instillation of the Preservative-free investigational lubricating eye drops in a Novelia
® eyedropper 
will be non-inferior to the monocular distance (4m) HLLC logMAR at 10-minutes after the installation 
of Blink® Tears eye drops in a multidose bottle. A non-inferiority margin of 0.[ADDRESS_831080] satisfy all of the following criteria to be enrolled in the study: 
 
Inclusion Criteria following Screening The subject must: 
1. Read, understand, and sign the STATEMENT OF IN FORMED CONSENT and receive a fully executed 
copy of the form. 
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 
3. Be between 18 and 69 (inclusive) years of age at the time of screening. 
4. By [CONTACT_6270]-report, habitually wear soft spherical contact [CONTACT_35482] a daily reusable or daily 
disposable wear modality (i.e., not extended wear modality). Habitual wear is defined as a minimum of [ADDRESS_831081] achieve visual acuity of 20/[ADDRESS_831082] lenses. 
3.3. Exclusion Criteria 
Potential subjects who meet any of the following criteria will be excluded from participating in the study:  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831083] not: 
1. Be currently pregnant or lactating. 
2. Be diabetic.  
3. Be currently using any ocular medications or ha ve any ocular infection of any type which may 
interfere with the clinical trial (at the investigator’s discretion). 
4. By [CONTACT_6270]-report, have any ocular or systemic disease, allergies, infection, or use of medication that might 
contraindicate or interfere with the clinical trial, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human 
Immunodeficiency Virus [HIV]), au toimmune disease (e.g., rheumatoid  arthritis, Sjögren’s syndrome), 
or history of serious mental illness or seizures. See section 9.[ADDRESS_831084] habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g., SynergEyes, SoftPerm) within the past [ADDRESS_831085] participated in any pharmaceuti cal or medical device related clinical  trial within 14 days prior to 
study enrollment.  
7. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an 
employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site. 
8. Be a current habitual user of prescription medication to treat dry eye and ocular discomfort, ocular 
steroids, or any medication (RX or OTC) except artificial tears, that would interfere with the clinical 
study (at the discretion of the investigator).  
9. Have any known allergy or sensitivity to ingredients that the investigational product may contain (e.g., 
Sodium Chlorite, Boric Acid, Sodium Borate Decahydrate, Sodium Chloride, Potassium Chloride, 
Calcium Chloride Dihydrate, Magnesium Chloride Hexahydrate, Polyethylene Glycol 400, Sodium 
Hyaluronate and Purified Water). 
 
Exclusion Criteria at Baseline Evaluation 
The subject must not: 
10. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities, or bulbar injection) or other corneal or ocular 
disease or abnormalities that contraindicate participation or may otherwise co mpromise study endpoints 
(including entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, history of recurrent corneal 
erosions, aphakia, moderate  or above corneal distortion, herpetic keratitis). 
11. Have a history of strabismus or amblyopia. 
12. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, cataract removal, retinal laser photocoagulation, etc.). 
13. Have any significant corneal distortion due to previous contact [CONTACT_13279], surgery, or pathology (At the discretion of the investigator). 
3.4. Enrollment Strategy 
Study subjects will be recruited from the Institution/clinical site’s subject database and/or utilizing Independent 
Ethics Committee (IEC) or Institutional Review Board (IRB) approved materials.  
 
4. STUDY DESIGN AND RATIONALE 
4.1. Description of Study Design 
This is a single-visit, multi-site, ra ndomized, single-masked, bilateral, active-controlled, non-dispensing, 2x2 
crossover study. Approximately [ADDRESS_831086] (HLLC) logMAR visual acuity under high illumination will be measured with their habitual contact [CONTACT_93867] & Johnson Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831087] is found to meet all eligibility criteria, the subjects will be assigned to receive the eyedrops in 
a randomized order. A single drop (Eyedrops #1) will first be placed on the right eye followed by [CONTACT_358503]. 
LogMAR visual acuity will then be recorded [ADDRESS_831088] eyedrop application on the right eye. 
This will be followed by a washout of 90 minutes. The second eyedrop (Eyedrops#2) as per the randomization 
schedule will then be placed on the right eye followed by [CONTACT_358503]. LogMAR visual acuity will be recorded [ADDRESS_831089] to be his/her own 
control. Furthermore, it is also desirable that the study encompass a variety of subjects wearing diverse brands or 
materials as well as different modalities of soft, spherical contact [CONTACT_13276], as the investigational product is intended 
to be compatible with all soft contact [CONTACT_624168]. Given a large distribution of possible types or brands, or 
materials of contact [CONTACT_13276], a crossover study was deemed to  be more relevant and applicable to investigate the 
potential outcomes.    
In addition to visual acuity investigation, this study will also be useful to explore the impact of the artificial tears to the fitting of subjects’ own habitual contact [CONTACT_624169] a crossover design. Moreover  
a previous study using the same marketed eyedrop as a control, employed a crossover design with a 90-minute 
washout to document the effects of lubricating eyedrops on low contrast LogMAR visual acuity.   
4.3. Enrollment Target and Study Duration 
 
A total of up to 45 subjects will be enrolled (informed consent signed) and the eyedrop application randomized in up to [ADDRESS_831090] 
selection criteria. The number of subjects targeted for randomization and completion are as follows: 
Table 1: Target number of subjects by [CONTACT_624170] [ADDRESS_831091] Article Allocation  
Subjects will be randomly assigned to one of two uni que sequence groups (Test/Control and Control/Test) to 
bilaterally receive two different test articles i. e., one investigational formulation in a Novelia® eyedropper and 
another marketed Blink® Tears eyedrops, one at a time over the same visit (Table 2).  
 
    
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831092] Quality Complaint (PQC) refers to any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of test 
articles after they have been released for clinical trial use.    Potential complaints may come from a variety of sources including but not limited to subjects, clinical research 
associates (CRA), clinical operations managers (COM), medical monitors, and site personnel, etc. The following 
are not considered product quality complaints: 
x Subject satisfaction inquiries reported via “Subjective Questionnaires” and “Patient Reported Outcomes 
(PRO).” 
x Clinical test articles that are stored improperly or damaged after receipt at the investigational site. 
x Damage deemed by [CONTACT_35513], and not indicative of a quality deficiency (i.e., tears, breakages, etc.), only in situations where there is no deficiency alleged 
by [CONTACT_423]. 
 Within [ADDRESS_831093] be recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA 
representative. In cases where the EDC system in use is not configured to send automatic notifications or when 
an EDC system is not used, the COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC 
has occurred.    Upon receipt of the EDC notification, the COM/CRA will contact [CONTACT_253429]:  
x Date the complaint was received/ recorded in the EDC System (Date of Sponsor Awareness). 
x Who received the complaint. 
x Study number. 
x Clinical site information (contact [CONTACT_2300], site ID, telephone number). 
x Lot number(s). 
x Unique Subject Identifier(s). 
x Indication of who first observed complaint (site personnel or subject). 
x OD/OS indication, along with whether the eyedrop was used. 
x Any related AE number if applicable. 
x Detailed complaint description (scheduled/unscheduled visit, time of eyedrop usage, symptoms, 
resolution of symptoms, etc.). 
x Eye Care Provider objective (slit lamp) findings if applicable. 
x Confirmation of product availability for return (and tracking information, if available), or rationale if 
product is not available for return  
 
 
Once a complaint is received, it will be assessed by [CONTACT_19569], CRA, or trained site personnel to determine if it is an Adverse Event/Serious Adverse Even t (AE/SAE). If the complaint results in an AE/SAE, the COM/CRA, or 
trained site personnel will follow section 13 of this protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these procedures also apply and will be executed in parallel.    
In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the PQC forms will be 
marked “Intentionally Left Blank” or “ILB”.  Justification for ILB must be documented.  
13. ADVERSE EVENTS 
13.1. Definitions and Classifications 
Adverse Event (AE) – An AE is “any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical produc t and which does not necessarily ha ve a causal relationship with this 
treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 32 of 108JJVC CONFIDENTIAL
laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not related to the medicinal (investigational) product.”  
 
An AE includes any condition (including a pre-existing condition) that: 
1. Was not present prior to the study but appeared or reappeared following initiation of the study. 
2. Was present prior to the study but worsened during the study. This would incl ude any condition resulting 
from concomitant illnesses, reactions to concomitant medications, or progression of disease states. 
NOTE: Pregnancy must be documented  as an adverse event and must be  reported to the clinical monitor 
and to the Sponsor immediately upon learning of the event.  
Serious Advers e Event (SAE) – An SAE is any adverse event that led to any of the following: 
x Death 
x Serious deterioration in the health of the subject that resulted in any of the following: 
x Life-threatening illness or injury 
x Permanent or persistent impairment of a body structure or a body function 
x Hospi[INVESTIGATOR_93790] 
x Medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to 
a body structure or a body function. 
x Chronic disease 
x Foetal distress, foetal death or a congenital physical or mental impairment of birth defect. 
 Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to: 
x Microbial Keratitis (MK) 
x Iritis (including cells in the anterior chamber) 
x Permanent decrease in best spectacle  corrected visual acuity equivale nt to 2 acuity lines or greater 
x Central Corneal Opacity 
x Central Corneal Neovascularization 
x Uveitis 
x Endophthalmitis 
x Hypopyon 
x Hyphemia 
x Penetration of Bowman’s Membrane 
x Persistent Epi[INVESTIGATOR_32958] 
x Limbal cell Damage leading to Conjunctivalization 
 
Significant Adverse Events  – are defined as events that are symptomatic and warrant discontinuation (temporary 
or permanent) of the test articles (excluding Serious Adverse Events). 
 
Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but not limited to the 
following: 
x Significant Infiltrative Events (SIE) 
x Any Temporary Loss of > 2 Lines of BSCVA 
x Other grade 3 or higher corneal findings, such as abrasions or edema 
x Co
rneal events - e.g. Epi[INVESTIGATOR_71155] (EKC) 
x Asymptomatic Corneal Scar 
x Any corneal event which necessitates temporary eyedrop discontinuation > 2 weeks 
 
Non-Significant Adverse Events  – are defined as those events that are usually asymptomatic and usually do not 
warrant discontinuation of tear supplement use but may cause further symptoms.  However, the Investigator may 
choose to prescribe treatment as a precautionary measure.    
Diagnoses and conditions that are considered Ocular No n-Significant Adverse Events include, but not limited to 
the following: 
x Non-significant Infiltrative Event (NSIE) Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 33 of 108JJVC CONFIDENTIAL
x Papi[INVESTIGATOR_19534] 
x Superficial Punctate Keratitis (SPK) 
x Conjunctivitis: Bacterial, Viral, Allergic 
x Blepharitis 
x Meibomianitis 
x Contact [CONTACT_32984] 
x Localized Allergic Reactions or infections 
x Any corneal event not explicitly defined as serious or significant adverse event, which necessitates 
temporary eyedrop discontinuation < 2 weeks 
 
Adverse Drug Reaction (ADR):  An ADR is referred to all “noxious and unintended responses to a drug 
product related to any dose where a causal relationship between a medical product and an adverse event is at 
least a reasonable possibility, i.e., the relationship cannot be ruled out.”   
13.2. Assessing Adverse Events 
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include: 
x Seriousness/Classifications (see definition in section 13.1). 
x Causality or Relatedness – i.e. the relationship between the test article, study treatment or study 
procedures and the adverse event (not related, unlikely related, possibly related, or related - see definition 
in section 13.2.1). 
x Adverse Event Severity – Adverse event severity is used to assess the degree of intensity of the adverse event (mild, moderate, or severe - see definition in section 13.2.2). 
x Outcome – not recovered or not resolved, recovering, or resolving, recovered, or resolved with sequelae, 
recovered, or resolved, death related to adverse event, or unknown. 
x Actions Taken – none, temporarily discontinued, permanently discontinued, or other. 
13.2.1.  Causality Assessment 
Causality Assessment – A determination of the relationship between an adverse event and th e test article. The 
test article relationship for each adverse event should be determined by [CONTACT_32981]: 
x Not Related- An adverse event that is not related to the use of the test article, study treatment or study 
procedures. 
x Unlikely Related – An adverse event for which an alternative explanation is more likely, e.g. concomitant 
treatment, concomitant disease(s), or the relationship of time suggests that a causal relationship is not 
likely. 
x Possibly Related – An adverse event that might be due to the use of the test article, or to the study 
treatment or study procedures. An alternative expl anation, e.g. concomitant treatment, concomitant 
disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship 
cannot be excluded. 
x Related – An adverse event that is listed as a possibl e adverse effect (device) or adverse reaction (drug) 
and cannot be reasonably explained by [CONTACT_624171], e.g. concomitant treatment of 
concomitant disease(s). The relationship in time is ve ry suggestive, e.g. it is confirmed by [INVESTIGATOR_5328]-challenge 
and re-challenge. 
13.2.2.  Severity Assessment 
Severity Assessment – A qualitative assessment of the degree of intensity of an adverse event as determined by 
[CONTACT_19577]/her by [CONTACT_423]. The assessment of severity is made irrespective of test 
article, study treatment or study procedure relationship or seriousness of the event and should be evaluated according to the following scale: 
x Mild – Event is noticeable to  the subject but is easily tolerated a nd does not interfere with the subject’s 
daily activities. 
x Moderate – Event is bothersome, possible requiring additional therapy, and may interfere with the subject’s daily activities. Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 34 of 108JJVC CONFIDENTIAL
x Severe – Event is intolerable, necessitates additional therapy or alteration of therapy and interferes with 
the subject’s daily activities. 
13.3. Documentation and Follow-Up of Adverse Events 
The recording and documenting of adverse events (ocular and non-ocular) begin when the subjects are exposed to the test article, study treatment or study procedure.  Adverse events reported before the use of test article, start of study treatment, or study procedures will be recorded as  medical history. However, if the condition deteriorates 
at any time during the study, it will be recorded and reported as an AE. Untoward medical events reported after the subject’s exit from the study will be recorded as adverse events at the discretion of the Investigator. 
 
Upon finding an adverse event, the Principal Investigat or will document the condition in the subject record and 
in the eCRFs and complete the Adverse Event eCRF.   
 Complete descriptions of all adverse events must be ava ilable in the subject record. All Adverse Events including 
local and systemic reactions not mee ting the criteria for “serious advers e events” shall be captured on the 
appropriate case report form or electro nic data system. All adverse events occurring while the subject is enrolled 
in the study must be documented appropriately regardless of relationship.   
 It is the Investigator’s responsibility to maintain documentation of each reported adverse event. All adverse events 
will be followed in accordance with applicable licensing requirements. Such documentation will include the 
following: 
x Adverse event (diagnosis not symptom). 
x Drawings or photographs (where appropriate) that detail the finding (e.g., size, location, and depth, etc.). 
x Date the clinical site was notified. 
x Date and time of onset. 
x Date and time of resolution. 
x Adverse event classification, severity, and relationship to test articles, as applicable. 
x Treatment regimen instituted (where appropriate), including concomitant medications prescribed, in 
accordance with app licable licensing requirements. 
x Any referral to another hea lth care provider if needed. 
x Outcome, ocular damage (if any). 
x Likely etiology. 
x Best corrected visual acuity at the discovery of the event and upon conclusion of the event, if the AE is 
related to the visual system. 
 
Upon discovery of an AE that is deemed ‘possibly related’ or ‘related’ to the test article or study procedures 
(whether related to the visual system or not), an AE review form  must be completed. Additional 
dated and initialed entries should be made at follow-up evaluations. Separate forms must be completed for each 
eye if the AE is bilateral.  
 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment eCRF. Where 
necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If 
cultures are collected, the date of culture collection and laboratory utilized will be recorded.  
 
Changes in the severity of an AE shall be documented to allow an assessment of the duration of the event at each level of intensity to be performed. Adverse events characterized as intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the assessment of  relationship to the Test Article shall also be clearly 
documented. 
 
Subjects who present with an adverse event shall be followed by [CONTACT_737], within licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or been satisfactorily resolved. If further treatment beyond licensure is required, the patient will be referred to the appropriate health care provider. The Investigator will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the 
study. If a subject is discont inued from the study, it will be the responsib ility of the Investigat or to record the 
reason for discontinuation. The Investigator will also document the adverse event appropriately and complete the Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831094] article, study treatment, or study procedures may be recorded as “ongoing” without 
further follow-up. 
 
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e-mail, facsimile, or telephone as soon as possible 
and no later than 24 hours from discovery for any serious /significant adverse events, and 2 days from discovery 
for any non-significant adverse event. In addition, a written report will be submitted by [CONTACT_079] 
[INVESTIGATOR_35451]/IRB according to their requirements (section 13.4.2). The report will comment whether the adverse 
event was considered to be related to the test article, study treatment or study procedures.  13.4.1.  Reporting Adverse Events to Sponsor 
Serious/Significan t Adverse Events 
The Investigator will inform the sponsor of all serious/significant adverse events occu rring during the study period 
as soon as possible by e-mail or telephone, but no later than 24 hours following discovery of the event. The Investigator is obligated to pursue and obtain information requested by [CONTACT_169767]. All subjects experiencing a serious/significant adverse event must be followed up and all outcomes must be reported. 
 
When medically necessary, the Investigator may break the randomization code to de termine the identity of the 
treatment that the subject received. The Sponsor and study monitor should be notified prior to unmasking the test articles. 
 
In the event of a serious/significant adverse event, the Investigator must: 
x Notify the Sponsor immediately. 
x Obtain and maintain in the subject’s records all pertinent medical information and medical judgment for 
colleagues who assisted in the treatment and follow-up of the subject. 
x Provide the Sponsor with a complete case history which includes a statement as to whether the event 
was or was not related to the use of the test article. 
x Notify the IEC/IRB as required by [CONTACT_6179]/IRB repor ting procedure according to national regulations. 
 
Non-Serious Adverse Events 
All non-serious adverse events, including non-serious adverse device effects, will be reported to the sponsor by 
[CONTACT_35521] 2 days from discovery. 
13.4.2.  Reporting Adverse Events to the Respon sible IEC/IRB and Health Authorities 
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the IEC/IRB’s written 
guidelines. Each clinical site will refer to and follow an y guidelines set forth by [CONTACT_19581]/IRB. Each 
clinical site will refer to and follow any guidelines set forth by [CONTACT_169768]. 
 
The Sponsor will report applicable Adverse Events to the local health authorities according to the written 
guidelines, including reporting timelines.  
13.5. Event of Special Interest 
None 
13.6. Reporting of Pregnancy 
Subjects reporting pregnancy (by [CONTACT_6270]-rep ort) during the study will be discontinued after the event is recorded as 
an Adverse Event. Once discontinued, pregnant participan ts and their fetuses will not be monitored for study 
related purposes. Pregnant participants are not discontinued from artificial tear solution related studies for safety concerns, but due to general concerns relating to pregnancy and solution use. Specifically, pregnant women are Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 36 of 108JJVC CONFIDENTIAL
Hypothesis Testing 
The null and alternative hypotheses for testing non-inferiority of the Preservative-free investigational lubricating 
eye drops compared to Blink® Tears eye drops with respect to monocu lar logMAR visual acuity are as follows: 
ܪ଴: ߤ்െߤ஼൒0.05  
 ܪ஺: ߤ்െߤ஼<0 . 0 5  
 Where, ߤ
் represents the mean logMAR score for the Preserva tive-free investigational lubricating eye drops, and 
ߤ஼ represents the mean l ogMAR score for the Blink® Tears eye drops. Non-inferiority will be declared if the 
upper bound of the 2-sided 95% confidence interval of the difference (the Preservative-free investigational 
lubricating eye drops – Blink® Tears eye drops) is less than the non-inferiority margin of 0.[ADDRESS_831095] be met for the study to be successful. 
14.6. Secondary Analysis  
There are no secondary analyses .  
14.7. Other Exploratory Analysis  
Summary statistical analysis will be provided for the following other observations: 
x Slit lamp findings using FDA scale 
x Snellen best corrected distance visual acuity 
x Subject reported ocular symptoms 
x Number of Adverse events 
x Number and reasons for discontinuation 
x Lens fitting assessments  
14.8. Interim Analysis 
No interim analysis is planned in this study.  
14.9. Procedure for Handling Missing Data and Drop-Outs 
All efficacy analyses will be performed on observed case  data. Missing values will not be imputed. The count of 
missing values will be included in the summary tables and listings. However, as this is a single visit study, subject 
dropout is not expected. In the event that more than 10% (4 subjects) have missing data, a sensitivity analysis will 
be conducted for the primary endpoint. using multiple im putation method. Full details regarding methods for the 
imputations will be outlined in SAP. 
14.10.   Procedure for Reporting Deviations from Statistical Plan  
The analysis will be conducted according to that specifi ed in above sections. There are no known reasons for 
which it is planned to deviate from th ese analysis methods. If for any reason a change is made, the change will be 
documented in the study report along with a justification for the change.  
15. DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645]/ARCHIVING 
15.1. Electronic Case Report  Form/Data Collection 
The data for this study will be captured on electronic case report forms (eCRFs) using the Clario EDC system. 
An authorized data origin ator will enter study data into the eCRFs using the EDC system. Data collected on 
equipment that is not captured in EDC will be formatted to the specification of the JJVC database manager and 
sent to JJVC for analysis. External data sources for this study are not applicable. 
 The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_737]. The sponsor or sponsor’s representatives will be 
authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study.  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 39 of 108JJVC CONFIDENTIAL
 
Edit checks, electronic queries, and audit trails are built into the system to  ensure accurate and complete data 
collection. Data will be transmitted from the clinical site to a secure central database as forms are completed or 
updated, ensuring information accuracy, security, and confidentiality. After the final database lock, the 
Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic 
media in PDF format for all of the study data. The IPP must be retained in the study files as a certified copy of 
the source data for the study.  The content and structure of the eCRFs are compliant with ISO14155:2020.
[ADDRESS_831096] should be available for the following:  
x subject identification 
x eligibility 
x study identification 
x study discussion 
x provision of and date of informed consent 
x visit dates 
x results of safety and efficacy parame ters as required by [CONTACT_760] 
x a record of all adverse events 
x follow-up of adverse events 
x medical history and concomitant medication 
x test article receipt/dis pensing/return records 
x date of study completion 
x reason for early discontinuation of test article or withdrawal from the study, if applicable 
 
The subject record is the eCRF or an external record. The author of an entry in the subject record must be 
identifiable. The first point of entry is considered to be the source record.  
Adverse event notes must be reviewed and initialed by [CONTACT_737]. 
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by [CONTACT_1034].  
 
16. DATA MANAGEMENT 
16.1. Access to Source Data/Document 
The Investigator/Institution will permit trial-related monitoring, audits, IEC/IRB review and regulatory 
inspection(s) by [CONTACT_20618]/documents. Should the clinical site be contact[CONTACT_35527]/IRB or regulatory authority, JJVC must be contact[CONTACT_19592] [ADDRESS_831097] and therefore may disclose it as required to other clinical investigators and to regulatory agencies. In order to allow the use of the information 
derived from this clinical study, the Investigator unders tands that he/she has an obligation to provide complete 
test results and all data developed during this study to the Sponsor. 
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, include the selection of qualified investigators and appropriate clinical sites and review of protocol procedures with the Principal Investigator. The Principal Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831098] access to study-relate d source data/documents and reports for the purpose of monitoring and 
auditing by [CONTACT_35529]. 
16.4. Data Monitoring Committee (DMC) 
Not applicable 
 
17. CLINICAL MONITORING 
The study monitors will maintain close contact [CONTACT_624172]’s designated 
clinical site personnel. The monitor’s responsibilities will include: 
x Ensuring that the investigation is being conducted according to the protocol, any subsequent versions, 
and regulatory requirements are maintained. 
x Ensuring the rights and wellbeing of subjects are protected. 
x Ensuring adequate resources, including facilities, labor atories, equipment, and qualified clinical site 
personnel. 
x Ensuring that protocol deviations are documented with corrective action plans, as applicable. 
x Ensuring that the clinical site has sufficient test article and supplies. 
x Clarifying questions regarding the study. 
x Resolving study issues or problems that may arise. 
x Reviewing of study records and source documentation verification in accordance with the monitoring 
plan. 
 
18. ETHICAL AND REGULATORY ASPECTS 
18.1. Study-Specific Design Considerations 
Potential subjects will be fully informed of the risks and requirements of the study, and, during the study, subjects will be given any new information that may affect their decision to continue participation. Subjects will be told that their consent to participate in the study is voluntary and may be withdrawn at any time with no reason given 
and without penalty or loss of benefits to which they would otherwise be entitled. Subjects will only be enrolled 
if the subject is fully able to understand the risks, benefits, and potential adverse events of the study and provide  
their consent voluntarily.  
18.2. Investigator Responsibility 
The Principal Investigator [INVESTIGATOR_353859], the investigati onal plan, according to ISO [ZIP_CODE]:2020,
1  ICH GCP E6 (R2)[ADDRESS_831099] maintain clinical study files in acco rdance with applicable regulatory 
requirements.   Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831100] (IEC/IRB) 
Before the start of the study, the Investigator (or Spons or when applicable) will prov ide the IEC/IRB with current 
and complete copi[INVESTIGATOR_23747] (where applicable): 
x Final protocol. 
x Sponsor-approved informed consent form (and any other written materials to be provided to the subjects) 
x Investigator’s Brochure (or equivalent information). 
x Sponsor-approved subject recruitment materials. 
x Information on compensation for study-related injuries or payment to subjects for participation in the 
study. 
x Investigator’s curriculum vitae, clinical licenses, or equivalent information (unless not required, as 
documented by [CONTACT_8134]/IRB). 
x Information regarding funding, name [CONTACT_19618],  institutional affiliations, other potential conflicts 
of interest, and incentives for subjects. 
x Any other documents that the IEC/IRB requests to fulfill its obligation. 
 
This study will be undertaken only afte r IEC/IRB has given full approval of the final protocol, the informed 
consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received 
a copy of this approval. This approval letter must be  dated and must clearly identify the documents being 
approved. 
 
During the study, the Investigator (or Sponsor when applicable) will send the following documents to the IEC/IRB 
for their review and approval, where appropriate: 
x Protocol revisions 
x Revision(s) to informed consent form and any other written materials to be provided to subjects 
x If applicable, new, or revised subject recruitment materials approved by [CONTACT_1034] 
x Revisions to compensation for study-related injuries or payment to subjects for participation in the study 
x Investigator’s Brochure revisions  
x Summaries of the status of the study (at least annually or at intervals stipulated in guidelines of the IEC/IRB) 
x Reports of adverse events that are serious, unanticipat ed, and associated with th e test articles, according 
to the IRB’s requirements 
x New information that may adversely affect the safety of the subjects or the conduct of the study 
x Major protocol deviations as required by [CONTACT_6179]/IRB 
x Report of deaths of subjects under the Investigator's care 
x Notification if a new Investigator is responsible for the study at the clinical site 
x Any other requirements of the IEC/IRB 
 For protocol revisions that increase subject risk, the revisions and applicable informed consent form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s).  
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request should be documented 
in writing. 
 
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB about the study completion. Documentation of this notification must be retained at the clinical site and a copy provided to the CRO or Sponsor as applicable. 
18.4. Informed Consent 
Each subject or their representative, must give written consent according to local requirements after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related 
activity. The consent form that is used must be approved by [CONTACT_19597]/IRB. The 
informed consent is in accordance with principles that originated  in the Declaration of Helsinki
2, International 
Committee on Harmonization  E6(R2)4 and ISO [ZIP_CODE]:[ZIP_CODE] guidelines.  
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831101]'s dated signature. After having obtained the consent, a copy of the informed consent form must be given 
to the subject. 
18.5. 
Privacy of Personal Data 
The collection, processing and disclosure of personal da ta and medical information related to the Study Subject, 
and personal data related to Principal Investigator [INVESTIGATOR_71158] (e.g., name, clinic address and 
phone number, curriculum vitae) is subject to comp liance with the Health In formation Portability and 
Accountability Act (HIPAA) in the [LOCATION_002]13  and other applicable personal data protection and security 
laws and regulations.[ADDRESS_831102] these data, to maintain the 
confidentiality of the person’s related health and medical information, to properly inform the concerned persons 
about the collection and processing of th eir personal data, to grant them reasonable access to their personal data 
and to prevent access by [CONTACT_35532]. 
 All information obtained during the course of the investig ation will be regarded as confidential. All personal data 
gathered in this trial will be treated in strictest confidence by [CONTACT_4718], monitors, Sponsor’s personnel, and 
IEC/IRB. No data will be disclosed to any third party without the express permission of the subject concerned, with the exception of Sponsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context 
of their investigation related activities that, as part of the investigation will have access to the CRFs and subject 
records.  The collection and processing of personal data from subj ects enrolled in this study w ill be limited to those data 
that are necessary to investigate the efficacy, safety, quality, and utility of the investigational product(s) used in this study. 
 
These data must be collected and processed with adequate precautions to ensure confidentiality and compliance with applicable data privacy protection laws and regulations. The Sponsor ensures that the personal data will be: 
x processed fairly and lawfully. 
x collected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes. 
x adequate, relevant, and not excessive in relation to said purposes. 
x accurate and, where necessary, kept current. 
 Explicit consent for the processing of personal data will be obtained from the participating subject before 
collection of data. Such consent should also address the transfer of the data to other entities and to other countries. 
 The subject has the right to request through the Investigator access to his personal data and the right to request rectification of any data that are not correct or complete. Reasonable steps should be taken to respond to such a 
request, taking into consideration the nature of the request, the conditions of the study, and the applicable laws 
and regulations. 
 
Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures or access, accidental or unlawful destruction, or acciden tal loss or alteration must be put in place. Sponsor 
personnel whose responsi bilities require access to personal data agree to keep the identity of study subjects 
confidential. 
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.[ADDRESS_831103] RETENTION 
In compliance with the ISO [ZIP_CODE]:[ZIP_CODE] guidelines, the Investigator/Institution will maintain all CRFs and all 
subject records that support the data collected from each subject, as well as all study documents as specified in 
ISO [ZIP_CODE]:2020,1 and all study documents as specified by [CONTACT_8146](s)14. The 
Investigator/Institution will take measures to prevent acci dental or premature destruction of these documents. 
 
Essential documents must be retained until at least two (2) years after the last approval of a marketing application 
in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least two (2) years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents will be retained for a l onger period if required by [CONTACT_3433] e applicable regulatory 
requirements or instructed by [CONTACT_1034]. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained. 
 If the responsible Investigator retires, relocates, or fo r other reasons withdraws from the responsibility of keepi[INVESTIGATOR_169746], custody must be transferred to a pe rson who will accept the respon sibility. The Sponsor must 
be notified in writing of the name [CONTACT_1640]. Under no circumstance shall the Investigator 
relocate or dispose of any study documents before  having obtained written approval from the Sponsor. 
 
If it becomes necessary for the Sponsor or the appropr iate regulatory authority to review any documentation 
relating to this study, the Investigator must permit access to such reports.  
If the Investigator has a question regarding retention of study records, he/she should contact [CONTACT_19599]. 
 
20. FINANCIAL CONSIDERATIONS 
Remuneration for study services and expenses will be set forth in detail in the Clinical Research Agreement. The 
Research Agreement will be signed by [CONTACT_169775] a JJVC management representative prior to 
study initiation. 
 JJVC reserves the right to withhold remuneration for costs associated with protocol violations such as: 
x Continuing an ineligible subject in the study. 
x Scheduling a study visit outside the subject’s acceptable visit range. 
 
JJVC reserves the right to withhold fi nal remuneration until all study related activities have been completed, such 
as: 
x Query resolution. 
x Case Report Form signature. 
x Completion of any follow-up action items. 
x  
21. PUBLICATION 
There is currently no plan to publish this outcome of this investigation. 
 
22. REFERENCES 
 
1. ISO [ZIP_CODE]:2020: Clinical investigation of medical de vices for human subjects — Good clinical practice. 
Available at: 
https://www.iso.org/standard/[ZIP_CODE].html 
2. Declaration of Helsinki – Ethical principles for Medical Research Involving Human Subjects. Available 
at: https://www.wma net/policies-post/wma-declara tion-of-helsinki-ethical-principles-for-medical-
research-involving-human-subjects/ 
3. [LOCATION_002] (US) Code of Federal Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR 
4. International Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP). Available at: 
https://www.ich.org/page/efficacy-guidelines  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 44 of 108JJVC CONFIDENTIAL
5. Ferrand K et al. Prevalence of diagnosed dry eye di sease in the united States among adults aged 18 years 
and older. AJO. 2017;(182):90-98.  
6. Clayton JA. 2018. New England Journal of Medicine . 378(23):2212-2223.  
7. M Figus, L Agnifili, M Lanzini, al e. Topi[INVESTIGATOR_265221]-free ophthalmic treatments: An unmet clinical 
need. Expert Opi[INVESTIGATOR_265222]. 2021 Jun 3;18(6):655-72. Expert Opi[INVESTIGATOR_265222] . 
2021 Jun 3;18(6):655-72.  
8. AD Pucker, SM Ng, Nichols J. Over the counter (OTC) artificial tear drops for dry eye syndrome. 
Cochrane Database of Systematic Reviews . 2016;(2) 
9. Joshi N. Investigator's Brochure: Product  in a Novelia eyedropper. Version 1.0. 2023. 
10. SAS Institute Inc: SAS® 9.4 Statements: Reference, Third Edition . SAS Institute Inc; 2014. 
11. Bishop M.  Study report for Clinical Investigation of Visual Acuity in Contact [CONTACT_624173] a Lipid-Based Lubricating Eye Drop. 
12. Stroup W. Mixed model procedures to assess power, precision, and sample sizes.  American Statistical 
Association . 1999; 
13. Health Information Portability and Accountability Act (HIPAA). Available at: 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html  
14.         Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical 
devices,  http://data.europa.e u/eli/reg/2017/745/2017-05-05 
  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 45 of 108JJVC CONFIDENTIAL
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) 
Not Applicable.  
  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 46 of 108JJVC CONFIDENTIAL
 
APPENDIX B: PATIENT INSTRUCTION GUIDE   
Patient instruction guides (PIG) will be provided separately.  
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 47 of 108JJVC CONFIDENTIAL
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) 
  Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 48 of 108JJVC CONFIDENTIAL
Drug Facts
Active Ingredient  Purpose
Polyethylene Glycol 400 0.25% .  .  .....Eye lubricant
Uses   ■  For the temporary relief of burning, 
irritation, and discomfort due to dryness of the eye or 
exposure to wind or sun.
■  May be used as a protectant against further irritation. 
Warnings
■  For external use only.
■  To avoid contamination, do not touch tip of 
container to any surface. Replace cap after using. 
■  Do not use if solution changes color or becomes cloudy.
Stop use and ask a doctor if:You experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than [ADDRESS_831104]. 
Directions
Instill 1 or 2 drops in the affected eye(s) as needed or as directed by [CONTACT_89635].
Inactive Ingredients 
Boric Acid; Calcium Chloride; Magnesium Chloride; Potassium Chloride; Puriﬁed Water; Sodium Borate; Sodium Chloride; Sodium Chlorite (OcuPure
® brand) 
as a preservative; Sodium Hyaluronate. 
Other Information
Use only if tape seals on top and bottom ﬂaps are intact.
RETAIN THIS CARTON FOR FUTURE REFERENCE.Lubricating Eye Dropsblink
ting Eye Drops
TearsTears
Discard solution [ADDRESS_831105] of China made in accordance with US FDA guidelines
Blink is a trademark of [COMPANY_012] Surgical Vision, Inc.No. 93286BT
© [COMPANY_012] 
Surgical Vision, Inc. 2017Santa Ana, CA 92705AM60870US12C
9587X
Revision Date: 07/2018Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 49 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 APPENDIX D:   
x  EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING 
x  LENS FITTING CHARACTERISTICS  
x  SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS 
x  DETERMINATION OF DISTANCE SPHE ROCYLINDRICAL REFRACTIVE ERROR 
x  BIOMICROSCOPY SCALE 
x  DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION 
x  DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE 
x  VISUAL ACUITY CHART LUMINANC E AND ROOM ILLUMINATION TESTING 
 
 
CR-6503, v 2.0  
Page 50 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 EXP ANDED SODIUM FLUORESCEIN CORNEAL STAINING 
CR-6503, v 2.0  
Page 51 of 108JJVC CONFIDENTIAL
Title:                        Expanded Sodium Fluorescein Corneal Staining
Document Type:       
Document Number: Revision Number:  6 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 55 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
  LENS FITTING CHARACTERISTICS 
 
  
CR-6503, v 2.0  
Page 58 of 108JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number: Revision Number:  6 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 63 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
  SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS   
CR-6503, v 2.0  
Page 64 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIVE 
ERROR 
 
  
CR-6503, v 2.0  
Page 66 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
  BIOMICROSCOPY SCALE 
 
  
CR-6503, v 2.0  
Page 72 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION 
 
   
CR-6503, v 2.0  
Page 78 of 108JJVC CONFIDENTIAL
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 80 of 108JJVC CONFIDENTIAL
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 82 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
  DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE 
 
  
CR-6503, v 2.0  
Page 83 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
  DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION 
 
  
CR-6503, v 2.0  
Page 87 of 108JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 89 of 108JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 90 of 108JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 91 of 108JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 92 of 108JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 93 of 108JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 94 of 108JJVC CONFIDENTIAL
Title:                          Visu al Acuity Chart Luminance and Room Illumination Testing 
Document Type:  
Document Number: Revision Number:  4 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
CR-6503, v 2.0  
Page 95 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
APPENDIX E:  GUIDE LINES FOR COVID-19 RISK MITIGATION 
CR-6503, v 2.0  
Page 96 of 108JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_169778]: CR-6503 Protocol Title: Clinical  Investigation of Visual Acuity in Contact [CONTACT_624174]: 2.[ADDRESS_831106] this study according to ISO [ZIP_CODE]:2020,
1 International Council for Harmonization Good 
Clinical Practice E6(R2) (ICH GCP),4 the Declaration of Helsinki,2 [LOCATION_002] (US) Code of Federal 
Regulations (CFR)3, and the pertinent individual country laws/regulations and to comply with its obligations, 
subject to ethical and safety considerations. I, as the Pr incipal Investigator, am responsible for ensuring that all 
clinical site personnel, including Sub-Investigators, adhere to all regulations and GCP guidelines regarding 
clinical trials during and after study completion.  I will assure that no deviation from or changes to the protocol will take place without prior agreement from the Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to 
eliminate an immediate hazard(s) to the trial participants. 
 
All clinical site personnel involved in the conduct of  this study have completed Human Subjects Protection 
Training.   I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about their 
obligations in meeting the above commitments. 
 
I shall not disclose the information contained in this protocol or any results obtained from this study without 
written authorization. 
 
I have read the suggested guidance provided by [CONTACT_19610]-19 risk mitigation, (COVID-19 
Work Instruction in the Appendix E of this protocol). I agree to conduct this study in compliance with local, state, governmental guidance for COVID-19 risks.   
Principal 
Investigator:    
 [INVESTIGATOR_197532] (Printed)   
 
Institution/Site:    
 Institution/Site Name 
 
    
 [CONTACT_16277]/Site Address   
 
 
 
CR-6503, v 2.0  
Page 108 of 108JJVC CONFIDENTIAL